Desvenlafaxine (Pristiq) is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used for major depressive disorder (MDD). It is the active O-desmethyl metabolite of venlafaxine (Effexor), approved as a separate drug in part because it undergoes minimal CYP2D6 metabolism — making its pharmacokinetics more predictable and reducing the drug interaction burden associated with venlafaxine's CYP2D6-dependent metabolism. Key risks include a discontinuation syndrome if stopped abruptly (taper required), serotonin syndrome potential with other serotonergic drugs, and MAOI contraindication. Blood pressure monitoring is recommended due to norepinephrine-mediated effects.
Desvenlafaxine
Uses & FDA Indications
Desvenlafaxine is FDA-approved for the treatment of major depressive disorder (MDD) in adults. It is indicated for the acute and maintenance treatment of depression, including prevention of relapse after initial response to treatment.
Off-label uses investigated in clinical research include vasomotor symptoms (hot flashes) associated with menopause — an application where venlafaxine and desvenlafaxine have demonstrated efficacy in randomized trials, particularly valuable for women who cannot use hormone therapy. Other investigated off-label uses include generalized anxiety disorder (GAD), fibromyalgia, and diabetic peripheral neuropathy, where the norepinephrine component of SNRI activity contributes to pain modulation.
Like all antidepressants, desvenlafaxine requires several weeks of consistent use before meaningful antidepressant effect is observed. The delayed onset is due to the time required for downstream receptor adaptation (desensitization of serotonin autoreceptors) rather than a lag in drug accumulation.
How It Works
Desvenlafaxine inhibits the reuptake transporters for both serotonin (SERT) and norepinephrine (NET), increasing the synaptic concentrations of both neurotransmitters. This is the same dual-reuptake inhibition mechanism shared by all SNRIs (venlafaxine, duloxetine, levomilnacipran).
Compared to venlafaxine, desvenlafaxine has a somewhat higher ratio of norepinephrine to serotonin reuptake inhibition — meaning its noradrenergic activity is relatively more prominent. Compared to duloxetine, desvenlafaxine has less pronounced norepinephrine potency. The clinical significance of these pharmacological differences is debated, as comparative efficacy trials have not established consistent advantages for any individual SNRI in antidepressant effect.
The pharmacokinetic rationale for desvenlafaxine as a distinct drug: venlafaxine requires CYP2D6 metabolism to form desvenlafaxine (its active form). CYP2D6 activity varies substantially between individuals — poor metabolizers achieve 4–5 times higher venlafaxine-to-desvenlafaxine ratios than extensive metabolizers, creating variable drug exposure. Desvenlafaxine, not requiring CYP2D6 for its own activity, sidesteps this variability and is also less prone to CYP2D6-mediated drug interactions that complicate venlafaxine therapy.
FDA BOXED WARNING — SUICIDALITY: Antidepressants including desvenlafaxine carry a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18–24) during the early months of treatment. This risk must be balanced against the clinical need for treatment. Desvenlafaxine is not FDA-approved for use in pediatric patients. Patients starting therapy should be monitored closely for clinical worsening and emergence of suicidal thoughts, particularly during the first several weeks and after dose changes.
Side Effects
Common
- Nausea — the most common early side effect; usually improves after 1–2 weeks; taking with food helps
- Headache
- Dry mouth
- Dizziness
- Insomnia or somnolence
- Hyperhidrosis (excessive sweating) — noradrenergic effect; can be bothersome long-term
- Sexual dysfunction — decreased libido, delayed or absent orgasm, erectile dysfunction; serotonergic mechanism; common across all SNRIs and SSRIs
- Constipation
- Blood pressure elevation — norepinephrine reuptake inhibition increases sympathetic tone; clinically significant at higher doses
Serious
- Serotonin syndrome — potentially fatal; risk with concurrent serotonergic drugs; presents as agitation, tremor, myoclonus, hyperthermia, autonomic instability
- Discontinuation syndrome — dizziness, nausea, brain zaps, irritability upon abrupt cessation; requires gradual taper
- Hypertension — clinically significant blood pressure increases, particularly at higher doses; requires monitoring
- Hyponatremia — syndrome of inappropriate antidiuretic hormone secretion (SIADH); more common in elderly; presents as confusion, weakness, seizures
- Bleeding — SNRIs inhibit platelet serotonin uptake, impairing platelet aggregation; increased risk of bleeding particularly when combined with NSAIDs or anticoagulants
- Angle-closure glaucoma — rare; mydriasis can precipitate acute angle-closure in susceptible patients
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue) | Life-threatening serotonin syndrome. MAO inhibitors prevent breakdown of excess serotonin, and concurrent SNRI use causes catastrophic serotonin accumulation. Combination is absolutely contraindicated. | Contraindicated — 14-day washout required between desvenlafaxine and MAOI in either direction |
| Serotonergic Drugs (other SNRIs/SSRIs, triptans, tramadol, fentanyl, lithium, St. John's Wort) | Additive serotonergic activity increases serotonin syndrome risk. Severity ranges from mild (tremor, diarrhea) to severe (fever, rigidity, death). | High — avoid combinations when possible; if required, use lowest effective doses and monitor closely |
| Anticoagulants and NSAIDs | Desvenlafaxine inhibits platelet serotonin reuptake, impairing platelet function. Combined with warfarin, direct oral anticoagulants, or NSAIDs, bleeding risk increases substantially — particularly GI bleeding. | Moderate-High — monitor for bleeding signs; consider gastroprotective agent if NSAID combination required |
| CYP3A4 Inhibitors (ketoconazole, ritonavir, clarithromycin) | Desvenlafaxine is partially metabolized by CYP3A4. Strong inhibitors can increase desvenlafaxine plasma concentrations modestly. | Low-Moderate — monitor for increased side effects; dose adjustment usually not required for mild CYP3A4 inhibitors |
| Drugs Metabolized by CYP2D6 (metoprolol, codeine, atomoxetine) | Desvenlafaxine is a mild inhibitor of CYP2D6. It can modestly increase levels of drugs metabolized by CYP2D6, though this effect is substantially less pronounced than with venlafaxine. | Low-Moderate — clinically meaningful for drugs with narrow therapeutic windows; less concern than with venlafaxine |
Warnings & Contraindications
Contraindications
- Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
- Starting an MAOI within 7 days of stopping desvenlafaxine
- Known hypersensitivity to desvenlafaxine, venlafaxine, or any excipient
Discontinuation Syndrome
Abrupt discontinuation or rapid dose reduction of desvenlafaxine commonly produces a discontinuation syndrome. Symptoms include dizziness, nausea, headache, irritability, insomnia, sensory disturbances described as "brain zaps" (brief electric shock-like sensations in the head), flu-like malaise, and anxiety. Desvenlafaxine's half-life of approximately 11 hours means these symptoms can begin within 24–48 hours of a missed dose. Patients should be advised never to stop desvenlafaxine abruptly and should always taper under medical supervision, with the taper rate adjusted based on individual response.
Blood Pressure
Norepinephrine reuptake inhibition by desvenlafaxine can cause dose-dependent increases in blood pressure and heart rate. Blood pressure should be measured before starting desvenlafaxine, at each dose change, and periodically during stable therapy. Preexisting hypertension should be well controlled before initiating treatment, and desvenlafaxine should be used with particular caution in patients with cardiovascular or cerebrovascular disease.
Pregnancy
Desvenlafaxine use late in pregnancy has been associated with neonatal complications, including respiratory distress, feeding difficulties, jitteriness, and irritability — a pattern sometimes called neonatal abstinence syndrome or neonatal adaptation syndrome. The decision to use desvenlafaxine during pregnancy requires careful individualized risk-benefit assessment balancing fetal risks against the risks of untreated maternal depression.
Check for serotonin syndrome risk and other interactions with desvenlafaxine.
Check Drug Interactions →Frequently Asked Questions
What is desvenlafaxine discontinuation syndrome?
Discontinuation syndrome is a cluster of symptoms that can occur when SNRIs and SSRIs are stopped abruptly or reduced too quickly. With desvenlafaxine, common discontinuation symptoms include dizziness, nausea, headache, irritability, anxiety, insomnia, "brain zaps" (brief electric shock-like sensations), and flu-like symptoms. Symptoms typically begin within 1–3 days of stopping and may last 1–3 weeks. Desvenlafaxine's relatively short half-life (~11 hours) means that blood levels drop quickly after a missed dose, making symptom onset fairly rapid. The standard approach is to taper the dose gradually over several weeks to months rather than stopping abruptly.
How does desvenlafaxine differ from venlafaxine?
Desvenlafaxine is the active metabolite of venlafaxine — when venlafaxine is metabolized in the liver by CYP2D6, it is converted to desvenlafaxine. Desvenlafaxine was approved as a separate drug because it does not itself require significant CYP2D6 metabolism, making its pharmacokinetics more predictable and reducing drug interactions related to CYP2D6. Venlafaxine's blood levels can vary substantially based on a patient's CYP2D6 metabolizer status, whereas desvenlafaxine is more consistent across patients. In practice, the clinical difference between equivalent doses of venlafaxine and desvenlafaxine is modest — many clinicians consider them therapeutically similar.
Can desvenlafaxine cause serotonin syndrome?
Yes. As an SNRI, desvenlafaxine increases serotonin in synapses by blocking its reuptake. When combined with other serotonergic drugs — MAO inhibitors, other SNRIs or SSRIs, triptans, tramadol, fentanyl, lithium, St. John's Wort — excess serotonin accumulation can produce serotonin syndrome. Symptoms range from mild (tremor, diarrhea, mild agitation) to severe (high fever, muscle rigidity, rapid heart rate, seizures, loss of consciousness). Concurrent use with MAO inhibitors is absolutely contraindicated due to the risk of fatal serotonin syndrome — a 14-day washout period is required when switching between desvenlafaxine and an MAOI.